Palonosetran: Phase III

MOGN and Helsinn presented data from study 99-03, an international Phase III double-blind trial in 563 patients receiving high or low-dose palonosetron 5-HT3 serotonin receptor antagonist

Read the full 261 word article

How to gain access

Continue reading with a
two-week free trial.